In this paper, Drs. Quax and Nossent and colleagues report on the identification of specific microRNAs that regulate genes in the pathway involved in neovascularization, including the 14q32 microRNA gene cluster. Idera’s proprietary GSO technology enabled inhibition of these specific microRNAs in both cell-based assays as well as in animal models. Treatment with GSOs led to microRNA-specific down-regulation and hence up-regulation of the microRNA’s target genes. In a mouse model of double femoral artery ligation, treatment with specific GSOs targeting the identified microRNAs led to improved blood flow recovery after ischemia, increased perfusion and full recovery of tissue perfusion. These data show that GSOs targeting specific microRNAs have therapeutic potential for neovascularization.
“In this important study, we identified a large cluster of microRNAs that is involved in the recovery of blood flow following cardiovascular events,” said Dr. Nossent. “Through our collaboration with Idera and our application of its GSOs, we were able to selectively target each of these microRNAs, elucidating their role in neovascularization. We were also able to demonstrate that inhibition of these specific microRNAs led to accelerated recovery of blood flow, thereby providing a rationale for a novel therapeutic approach.”
“GSOs are novel structures designed to overcome the limitations of the currently practiced antisense technology, with a goal of providing an increased therapeutic index,” said
Authors of the paper are
About Gene Silencing Oligonucleotides
Idera's gene silencing oligonucleotides (GSOs) are single-stranded RNA or DNA constructs with two exposed 3'-ends that are complementary to targeted mRNA sequences of therapeutic interest. In preclinical studies, GSOs have inhibited gene expression in vivo without requiring a delivery enhancement technology. GSOs are covered by issued (#8,431,544) and pending patents around the world.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding the Company’s strategy, future operations, collaborations, intellectual property, cash resources, financial position, future revenues, projected costs, prospects, plans, and objectives of management, are forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Idera cannot guarantee that it will actually achieve the plans, intentions or expectations disclosed in its forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. There are a number of important factors that could cause Idera’s actual results to differ materially from those indicated or implied by its forward-looking statements. Factors that may cause such a difference include: whether results obtained in preclinical studies and clinical trials such as the results described in this release will be indicative of the results that will be generated in future clinical trials; whether products based on Idera’s technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the
Most Popular Stories
- Bently Creates Alabama Small Business Commission
- Is Alibaba's IPO Price a Fairytale?
- Kardashian: Kanye Never Told Fan in Wheelchair to Stand Up
- Los Angeles Angels Clinch Playoff Spot
- U.S. Tobacco Growers Lose Last of Price Supports
- CalPERS Pulls Out of Hedge Funds
- U.S. Producer Prices Held Steady in August
- Sanctions Push Russian Ruble to Historic Low
- Scottish Leaders Scramble for Votes on Independence
- When to Say No to Investors, Yes to Mentors